Larimar Therapeutics (LRMR) Operating Expenses (2013 - 2026)
Larimar Therapeutics' (LRMR) quarterly Operating Expenses came in at $64.0 million in Q4 2025, up 104.58% YoY from $31.3 million in Q4 2024, and up 29.33% on a QoQ basis from $49.5 million in Q3 2025.
Larimar Therapeutics (LRMR) Operating Expenses (2013 - 2026) Analysis & Trends
Larimar Therapeutics (LRMR) has 13 years of Operating Expenses data on file, last reported at $64.0 million in Q4 2025.
- Quarterly Operating Expenses rose 104.58% year-over-year to $64.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $172.5 million (up 89.79% YoY) and the FY2025 annual result came in at $172.5 million, up 89.79% from the prior year.
- Operating Expenses grew to $64.0 million in Q4 2025, from $49.5 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $64.0 million in Q4 2025 to a low of $7.6 million in Q1 2023.
- A 5-year average of $19.6 million and a median of $13.4 million in 2021 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses tumbled 49.12% — and 2025, when it soared 171.02%.
- Tracing LRMR's Operating Expenses over 5 years: stood at $9.1 million in 2021, then gained by 14.89% to $10.4 million in 2022, then surged by 35.66% to $14.2 million in 2023, then jumped by 120.96% to $31.3 million in 2024, then soared by 104.58% to $64.0 million in 2025.
- The last three Operating Expenses figures came in at $64.0 million (Q4 2025), $49.5 million (Q3 2025), and $27.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Larimar Therapeutics | 452.93 Mn | 296.66 Mn | - | 34.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.35 Mn |
| Dec 31, 2025 | 64.02 Mn |
| Sep 30, 2025 | 49.50 Mn |
| Jun 30, 2025 | 27.79 Mn |
| Mar 31, 2025 | 31.19 Mn |
| Dec 31, 2024 | 31.29 Mn |
| Sep 30, 2024 | 18.26 Mn |
| Jun 30, 2024 | 24.60 Mn |
| Mar 31, 2024 | 16.73 Mn |
| Dec 31, 2023 | 14.16 Mn |
| Sep 30, 2023 | 10.34 Mn |
| Jun 30, 2023 | 9.62 Mn |
| Mar 31, 2023 | 7.64 Mn |
| Dec 31, 2022 | 10.44 Mn |
| Sep 30, 2022 | 8.51 Mn |
| Jun 30, 2022 | 8.69 Mn |
| Mar 31, 2022 | 8.89 Mn |
| Dec 31, 2021 | 9.09 Mn |
| Sep 30, 2021 | 16.73 Mn |
| Jun 30, 2021 | 12.54 Mn |